BR112022013547A2 - Métodos para potencializar a farmacocinética, para aumentar a concentração plasmática e a vigília ou diminuir a sonolência excessiva, e, composição - Google Patents
Métodos para potencializar a farmacocinética, para aumentar a concentração plasmática e a vigília ou diminuir a sonolência excessiva, e, composiçãoInfo
- Publication number
- BR112022013547A2 BR112022013547A2 BR112022013547A BR112022013547A BR112022013547A2 BR 112022013547 A2 BR112022013547 A2 BR 112022013547A2 BR 112022013547 A BR112022013547 A BR 112022013547A BR 112022013547 A BR112022013547 A BR 112022013547A BR 112022013547 A2 BR112022013547 A2 BR 112022013547A2
- Authority
- BR
- Brazil
- Prior art keywords
- wakeness
- composition
- methods
- increase
- reduce excessive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959514P | 2020-01-10 | 2020-01-10 | |
| PCT/US2021/012447 WO2021142083A1 (en) | 2020-01-10 | 2021-01-07 | A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013547A2 true BR112022013547A2 (pt) | 2022-09-06 |
Family
ID=74418549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013547A BR112022013547A2 (pt) | 2020-01-10 | 2021-01-07 | Métodos para potencializar a farmacocinética, para aumentar a concentração plasmática e a vigília ou diminuir a sonolência excessiva, e, composição |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12594269B2 (https=) |
| EP (1) | EP4087534A1 (https=) |
| JP (1) | JP7728264B2 (https=) |
| KR (1) | KR20220127245A (https=) |
| CN (1) | CN115226390B (https=) |
| AU (1) | AU2021205892B2 (https=) |
| BR (1) | BR112022013547A2 (https=) |
| CA (1) | CA3167050A1 (https=) |
| MX (1) | MX2022008392A (https=) |
| WO (1) | WO2021142083A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI4065585T3 (fi) | 2019-11-25 | 2025-09-26 | Alkermes Inc | Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| AR130709A1 (es) | 2022-10-07 | 2025-01-08 | Kissei Pharmaceutical | Compuesto de ciclopentano |
| KR20250085056A (ko) | 2023-12-05 | 2025-06-12 | 안희태 | 국궁 과녁에서 영역 구분 센서의 구성 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ524104A (en) * | 2000-09-08 | 2004-12-24 | Pharmacia Italia S | Exemestane as chemopreventing agent |
| HK1224173A1 (zh) | 2013-03-14 | 2017-08-18 | Pharmacyclics Llc | 布鲁顿氏酪氨酸激酶抑制剂和cyp3a4抑制剂的组合 |
| PL3411358T3 (pl) | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
| CA3032813A1 (en) | 2016-08-04 | 2018-02-08 | Gilead Sciences, Inc. | Cobicistat for use in cancer treatments |
| BR112022004576A2 (pt) | 2019-09-13 | 2022-06-14 | Takeda Pharmaceuticals Co | Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica |
| CA3154321A1 (en) | 2019-09-13 | 2021-03-18 | Takeda Pharmaceutical Company Limited | Tak-925 for use in treating narcolepsy |
-
2021
- 2021-01-07 MX MX2022008392A patent/MX2022008392A/es unknown
- 2021-01-07 WO PCT/US2021/012447 patent/WO2021142083A1/en not_active Ceased
- 2021-01-07 CA CA3167050A patent/CA3167050A1/en active Pending
- 2021-01-07 US US17/791,302 patent/US12594269B2/en active Active
- 2021-01-07 EP EP21702564.2A patent/EP4087534A1/en active Pending
- 2021-01-07 AU AU2021205892A patent/AU2021205892B2/en active Active
- 2021-01-07 CN CN202180017795.5A patent/CN115226390B/zh active Active
- 2021-01-07 KR KR1020227023475A patent/KR20220127245A/ko active Pending
- 2021-01-07 JP JP2022542294A patent/JP7728264B2/ja active Active
- 2021-01-07 BR BR112022013547A patent/BR112022013547A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021142083A1 (en) | 2021-07-15 |
| AU2021205892A1 (en) | 2022-08-18 |
| US12594269B2 (en) | 2026-04-07 |
| US20230029486A1 (en) | 2023-02-02 |
| AU2021205892B2 (en) | 2026-04-23 |
| CN115226390B (zh) | 2026-03-20 |
| JP2023510332A (ja) | 2023-03-13 |
| EP4087534A1 (en) | 2022-11-16 |
| JP7728264B2 (ja) | 2025-08-22 |
| KR20220127245A (ko) | 2022-09-19 |
| CA3167050A1 (en) | 2021-07-15 |
| CN115226390A (zh) | 2022-10-21 |
| MX2022008392A (es) | 2022-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022013547A2 (pt) | Métodos para potencializar a farmacocinética, para aumentar a concentração plasmática e a vigília ou diminuir a sonolência excessiva, e, composição | |
| BR112021017890A2 (pt) | Composição líquida compreendendo um anticorpo do receptor alfa de interleucina-4 humana | |
| BR112023015715A2 (pt) | Inibidor de cdk | |
| BR112015008708A2 (pt) | composição para clivagem de dna alvo compreendendo um rna guia específico para o dna alvo e ácido nucleico que codifica proteína cas ou proteína cas e uso da mesma | |
| BR112022002059A2 (pt) | Formas sólidas de um inibidor de hpk1 | |
| CL2019000586A1 (es) | Composiciones de toxinas clostridiales no proteicas. | |
| DK1372608T3 (da) | Medicinske aerosolformuleringer | |
| BR112014019262A8 (pt) | Composições orais veterinárias parasíticas compreendendo ingredientes ativos de ação sistêmica, métodos e uso das mesmas | |
| BR112022022922A2 (pt) | Composições para aumentar a meia-vida de um agente terapêutico em caninos e métodos de uso | |
| BRPI0317696B8 (pt) | composição para branqueamento | |
| UY31209A1 (es) | Uso de homo y copolimeros para la estabilización de formulaciones de principios activos | |
| CO2022004596A2 (es) | Tak-925 para uso en el tratamiento de la narcolepsia | |
| MX387478B (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| BR112022024156A2 (pt) | Compostos heterocílicos antelmínticos | |
| BR112021023832A2 (pt) | Métodos e composições para geração de óxido nítrico e usos dos mesmos | |
| PE20131324A1 (es) | Formulacion subcutanea de anticuerpo anti-her2 | |
| BRPI0412029A (pt) | formulações para microprojeções revestidas contendo contra-ìons não-voláteis | |
| CL2012000821A1 (es) | Composicion inmunogenica de reovirus de peces (prv) que comprende acido nucleico del prv; uso de la composicion inmunogenica que sirve para preparar un medicamento util para tratar afecciones de infeccion por prv en un animal. | |
| MX2025012087A (es) | Piridazinonas y metodos de uso de estas | |
| UY36542A (es) | Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa | |
| BR112022008504A2 (pt) | Composição de sabão | |
| BR112019003136A2 (pt) | forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo | |
| SE0302546D0 (sv) | New compounds | |
| BR112022026699A2 (pt) | Mecanismo de liberação de fragrâncias, método e usos do mesmo | |
| BRPI0516077A (pt) | composições antimicrobianas compreendendo um agente natural selecionado de ácido gálico, eucalipotol, naringina, um composto de ácido jasmÈnico e qualquer combinação destes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A ANUIDADE. |
|
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |